Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CYH33 |
Synonyms | |
Therapy Description |
CYH33 is a selective PIK3CA inhibitor that blocks PI3K signaling, resulting in increased cell cycle arrest and reduced tumor growth (PMID: 30003928; Cancer Res 2018;78(13 Suppl):Abstract nr LB-268). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYH33 | PIK3CA inhibitor 16 | CCYH33 is a PIK3CA inhibitor that suppresses the activation of Pi3k/Akt/Mtor signaling, which potentially induces cell cycle arrest and inhibits tumor growth (PMID: 30003928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB2 amp PIK3CA C420R | breast cancer | sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA C420R and ERBB2 (HER2) amplification in culture (PMID: 30003928). | 30003928 |
ERBB2 amp PIK3CA E545K | breast cancer | predicted - sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 30003928). | 30003928 |
PIK3CA H1047R | breast cancer | sensitive | CYH33 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R in culture, inhibited tumor progression in a transgenic mouse model, and induced cell cycle arrest, and inhibited PI3K signaling and tumor growth in cell line xenograft models (PMID: 30003928). | 30003928 |
PIK3CA mutant | breast cancer | predicted - sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to CYH33 compared to cell lines with wild-type PIK3CA in culture (p<0.01) (PMID: 30003928). | 30003928 |
ERBB2 amp PIK3CA H1047R | breast cancer | sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R and ERBB2 (HER2) amplification in culture (PMID: 30003928). | 30003928 |
ERBB2 amp PIK3CA K111N | breast cancer | predicted - sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification in culture (PMID: 30003928). | 30003928 |
Unknown unknown | breast cancer | not applicable | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of 56% (18/32) of breast cancer cell lines in culture and demonstrated increased activity compared to Piqray (Alpelisib) (PMID: 30003928). | 30003928 |
PIK3CA P539R | breast cancer | predicted - sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 30003928). | 30003928 |
ERBB2 amp | breast cancer | sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines harboring ERBB2 (HER2) amplification demonstrated increased sensitivity to CYH33 compared to cells with normal ERBB2 (HER2) expression in culture (p<0.05) (PMID: 30003928). | 30003928 |
PIK3CA E545K | breast cancer | predicted - sensitive | CYH33 | Preclinical - Cell culture | Actionable | In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 30003928). | 30003928 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|